PROTAGONIST THERAPEUTICS INC (PTGX)
US74366E1029 - Common Stock
We assign a fundamental rating of 6 out of 10 to PTGX. PTGX was compared to 564 industry peers in the Biotechnology industry. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability. PTGX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
PTGX had positive earnings in the past year.
PTGX had a positive operating cash flow in the past year.
In the past 5 years PTGX always reported negative net income.
In the past 5 years PTGX always reported negative operating cash flow.
1.2 Ratios
PTGX has a Return On Assets of 28.29%. This is amongst the best in the industry. PTGX outperforms 98.92% of its industry peers.
With an excellent Return On Equity value of 32.12%, PTGX belongs to the best of the industry, outperforming 98.38% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 21.06%, PTGX belongs to the top of the industry, outperforming 98.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.29% | ||
| ROE | 32.12% | ||
| ROIC | 21.06% |
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PTGX (52.76%) is better than 98.92% of its industry peers.
The Operating Margin of PTGX (46.05%) is better than 99.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 46.05% | ||
| PM (TTM) | 52.76% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PTGX is creating value.
The number of shares outstanding for PTGX has been increased compared to 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PTGX has an Altman-Z score of 20.55. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
PTGX's Altman-Z score of 20.55 is amongst the best of the industry. PTGX outperforms 92.28% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.55 |
ROIC/WACC1.99
WACC10.61%
2.3 Liquidity
A Current Ratio of 10.70 indicates that PTGX has no problem at all paying its short term obligations.
The Current ratio of PTGX (10.70) is better than 83.30% of its industry peers.
PTGX has a Quick Ratio of 10.70. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.70, PTGX belongs to the top of the industry, outperforming 83.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 |
3. Growth
3.1 Past
PTGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 201.53%, which is quite impressive.
PTGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 125.73%.
PTGX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.17% yearly.
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 19.79% on average over the next years. This is quite good.
Based on estimates for the next years, PTGX will show a very strong growth in Revenue. The Revenue will grow by 49.67% on average per year.
EPS Next Y270.01%
EPS Next 2Y-1.87%
EPS Next 3Y-10.07%
EPS Next 5Y19.79%
Revenue Next Year695.71%
Revenue Next 2Y41.96%
Revenue Next 3Y47.31%
Revenue Next 5Y49.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PTGX is valuated correctly with a Price/Earnings ratio of 14.88.
Based on the Price/Earnings ratio, PTGX is valued cheaply inside the industry as 96.95% of the companies are valued more expensively.
PTGX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.41.
PTGX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.88 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaply inside the industry as 97.49% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PTGX is valued cheaper than 98.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.17 | ||
| EV/EBITDA | 10.16 |
4.3 Compensation for Growth
PTGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTGX's earnings are expected to decrease with -10.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y-1.87%
EPS Next 3Y-10.07%
5. Dividend
5.1 Amount
PTGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROTAGONIST THERAPEUTICS INC
NASDAQ:PTGX (1/3/2025, 8:00:01 PM)
After market: 39.57 0 (0%)39.57
+0.59 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.9%
Inst Owner Change3.98%
Ins Owners1.21%
Ins Owner Change-0.86%
Market Cap2.33B
Analysts83.75
Price Target58.65 (48.22%)
Short Float %6.36%
Short Ratio5.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.69%
Min EPS beat(2)12.85%
Max EPS beat(2)18.53%
EPS beat(4)4
Avg EPS beat(4)399.61%
Min EPS beat(4)12.85%
Max EPS beat(4)1399.31%
EPS beat(8)6
Avg EPS beat(8)202.14%
EPS beat(12)10
Avg EPS beat(12)141.03%
EPS beat(16)12
Avg EPS beat(16)104.67%
Revenue beat(2)1
Avg Revenue beat(2)36.16%
Min Revenue beat(2)-48.93%
Max Revenue beat(2)121.25%
Revenue beat(4)3
Avg Revenue beat(4)56.92%
Min Revenue beat(4)-48.93%
Max Revenue beat(4)121.25%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.75%
PT rev (3m)9.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)82.8%
EPS NY rev (1m)18.1%
EPS NY rev (3m)39.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)234.2%
Revenue NY rev (1m)5.58%
Revenue NY rev (3m)8.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.88 | ||
| Fwd PE | N/A | ||
| P/S | 7.2 | ||
| P/FCF | 10.17 | ||
| P/OCF | 10.12 | ||
| P/B | 4.38 | ||
| P/tB | 4.38 | ||
| EV/EBITDA | 10.16 |
EPS(TTM)2.66
EY6.72%
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)3.89
FCFY9.84%
OCF(TTM)3.91
OCFY9.88%
SpS5.5
BVpS9.03
TBVpS9.03
PEG (NY)0.06
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.29% | ||
| ROE | 32.12% | ||
| ROCE | 26.66% | ||
| ROIC | 21.06% | ||
| ROICexc | 130.08% | ||
| ROICexgc | 130.08% | ||
| OM | 46.05% | ||
| PM (TTM) | 52.76% | ||
| GM | N/A | ||
| FCFM | 70.79% |
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.41% | ||
| Cap/Sales | 0.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.46% | ||
| Profit Quality | 134.17% | ||
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 | ||
| Altman-Z | 20.55 |
F-Score7
WACC10.61%
ROIC/WACC1.99
Cap/Depr(3y)91.94%
Cap/Depr(5y)94.77%
Cap/Sales(3y)2.68%
Cap/Sales(5y)86.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
EPS Next Y270.01%
EPS Next 2Y-1.87%
EPS Next 3Y-10.07%
EPS Next 5Y19.79%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Sales Q2Q%N/A
Revenue Next Year695.71%
Revenue Next 2Y41.96%
Revenue Next 3Y47.31%
Revenue Next 5Y49.67%
EBIT growth 1Y197.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year220.8%
EBIT Next 3Y34.78%
EBIT Next 5YN/A
FCF growth 1Y319.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.64%
OCF growth 3YN/A
OCF growth 5YN/A